Modifying plasma low-density lipoprotein and high-density lipoprotein cholesterol: what combinations are available in the future?

@article{Kastelein2005ModifyingPL,
  title={Modifying plasma low-density lipoprotein and high-density lipoprotein cholesterol: what combinations are available in the future?},
  author={John J. P. Kastelein},
  journal={The American journal of cardiology},
  year={2005},
  volume={96 9A},
  pages={20K-27K; discussion 34K-35K}
}
Despite a growing body of research on the benefit of combination drug therapy for dyslipidemia in the metabolic syndrome or diabetes mellitus, there are insufficient outcome data on the use of combination therapy as well as inadequate data to compare certain combination regimens. The focus of the therapeutic approach in treating the metabolic syndrome has been almost exclusively on low-density lipoprotein (LDL) cholesterol for approximately the past 10 years, and specifically on statin therapy… CONTINUE READING
2 Citations
0 References
Similar Papers

Similar Papers

Loading similar papers…